ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgraded Supernus Pharmaceuticals Inc (NASDAQ:SUPN), saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
“That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product,” the analyst adds.
Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults.
In the second quarter of 2024, net sales of Qelbree increased 92% year over year to $59.4 million, and total IQVIA prescriptions were 184,342, up 26%.
Piper writes that the management’s focus on optimizing Qelbree’s net economics, such as reducing copay assistance, suggests that future volume growth may be more modest. While initial estimates projected peak sales nearing $500 million, Piper writes that $400 million is a more realistic …
Full story available on Benzinga.com